Mastodon

Oxazepam-Ferein (Tablets) Instructions for Use

Marketing Authorization Holder

Bryntsalov-A, JSC (Russia)

ATC Code

N05BA04 (Oxazepam)

Active Substance

Oxazepam (Rec.INN registered by WHO)

Dosage Form

Bottle Rx Icon Oxazepam-Ferein Tablets 10 mg: 20, 40, 50, or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets 1 tab.
Oxazepam 10 mg

10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
20 pcs. – blister packs (2) – cardboard packs.
20 pcs. – blister packs (5) – cardboard packs.

Clinical-Pharmacological Group

Anxiolytic (tranquilizer)

Pharmacotherapeutic Group

Anxiolytic agent (tranquilizer)

Pharmacological Action

Anxiolytic agent (tranquilizer) from the group of benzodiazepine derivatives. It has anxiolytic and sedative effects. It possesses anticonvulsant and central muscle relaxant activity.

The mechanism of action is associated with the enhancement of GABA-ergic processes in the brain. It primarily affects the activating reticular formation of the brain, reducing the perception of impulses from sensory receptors to the limbic system and diminishing emotional coloring.

Pharmacokinetics

After oral administration, it is absorbed slowly and completely. Plasma protein binding is 97%. Cmax is achieved in 1-4 hours and is 450 ng/ml after a 30 mg dose.

It penetrates the blood-brain barrier, placental barrier, and into breast milk. It is metabolized in the liver to form glucuronides, which have no pharmacological activity. T1/2 is 5-15 hours.

It is excreted by the kidneys and in feces. Css is noted after 1-3 days of treatment. Accumulation upon repeated administration is minimal (refers to benzodiazepines with short and medium T1/2), elimination after discontinuation of treatment is rapid.

Indications

Neuroses, sleep disorders, psychovegetative disorders. Autonomic disorders in women associated with menstrual cycle disorders or the climacteric period, as well as with severe premenstrual syndrome.

Reactive depressions (as part of combination therapy).

ICD codes

ICD-10 code Indication
F31 Bipolar affective disorder
F32 Depressive episode
F33 Recurrent depressive disorder
F41.2 Mixed anxiety and depressive disorder
F45.3 Somatoform dysfunction of the autonomic nervous system
F48.0 Neurasthenia
F48.9 Unspecified neurotic disorder
F51.2 Nonorganic disorders of the sleep-wake schedule
N94.3 Premenstrual tension syndrome
N95.1 Menopausal and other perimenopausal disorders
N95.3 States associated with artificial menopause
ICD-11 code Indication
6A60.Z Bipolar type I disorder, unspecified
6A61.Z Bipolar type II disorder, unspecified
6A6Z Bipolar or similar disorder, unspecified
6A70.Z Single episode depressive disorder, unspecified
6A71.Z Recurrent depressive disorder, unspecified
6A73 Mixed depressive and anxiety disorder
6A8Z Affective disorders, unspecified
6B6Z Dissociative disorders, unspecified
6C20.Z Bodily distress disorder, unspecified
6C9Z Disruptive behavior or dissocial disorders, unspecified
7B2Z Sleep-wake cycle disorders, unspecified
GA30.00 Menopausal or climacteric states in women
GA30.3 States associated with artificial menopause
GA34.40 Premenstrual tension syndrome

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Establish the dosage individually based on clinical indication and therapeutic response.

Administer a daily dose ranging from 10 mg to 120 mg.

For mild to moderate anxiety disorders, initiate with 10-15 mg administered two to three times daily.

For severe anxiety states, agitation, or alcohol withdrawal, use 15-30 mgtwo to three times daily.

For sleep induction in insomnia, administer a single dose of 15-25 mg at bedtime.

For geriatric or debilitated patients, initiate therapy at the lower end of the dosage range ( 10 mg once or twice daily).

Adjust the dose cautiously based on tolerance and clinical need.

The maximum daily dose should not exceed 120 mg.

Determine the duration of treatment individually; avoid prolonged use to minimize risk of dependence.

Upon discontinuation, gradually reduce the dosage to prevent withdrawal symptoms or rebound phenomena.

Adverse Reactions

From the nervous system at the beginning of treatment (especially in elderly patients): drowsiness, dizziness, fatigue, impaired concentration, ataxia, unsteady gait and poor coordination of movements, lethargy, blunted emotions, slowed mental and motor reactions; rarely – headache, euphoria, depression, tremor, depressed mood, stupor, memory impairment, dystonic extrapyramidal reactions (uncontrolled movements, including eye movements), weakness, muscle weakness during the day, dysarthria (slurred speech), confusion; extremely rarely – paradoxical reactions (aggressive outbursts, psychomotor agitation, fear, suicidal tendency, muscle spasm, hallucinations, acute agitation, irritability, anxiety, insomnia).

From the hematopoietic system leukopenia, neutropenia, agranulocytosis (chills, hyperthermia, sore throat, unusual fatigue or weakness), anemia, thrombocytopenia.

From the digestive system dry mouth or salivation, heartburn, nausea, vomiting, anorexia, constipation, diarrhea, impaired liver function, increased activity of hepatic transaminases and alkaline phosphatase, jaundice.

From the urinary system urinary incontinence, urinary retention, impaired renal function.

From the reproductive system increased or decreased libido, dysmenorrhea.

Allergic reactions skin rash, itching.

Effect on the fetus teratogenicity, CNS depression, respiratory depression and suppression of the sucking reflex in newborns whose mothers used the drug.

Other habituation, drug dependence, decreased blood pressure; rarely – respiratory center depression, visual impairment (diplopia), bulimia, weight loss, tachycardia, anterograde amnesia.

With a sharp dose reduction or discontinuation of use withdrawal syndrome (irritability, headache, anxiety, agitation, excitement, feeling of fear, nervousness, sleep disturbance, dysphoria, spasm of smooth muscles of internal organs and skeletal muscles, depersonalization, increased sweating, depression, nausea, vomiting, tremor, perception disorders, including hyperacusis, paresthesia, photophobia, tachycardia, convulsions, hallucinations, rarely – acute psychosis).

Contraindications

Coma, shock, acute alcohol intoxication with weakening of vital functions, acute intoxication with drugs that have a depressant effect on the central nervous system (narcotic, hypnotic and psychotropic drugs), myasthenia gravis, closed-angle glaucoma (acute attack or predisposition), severe COPD (progression of the degree of respiratory failure), acute respiratory failure, severe depression (suicidal tendencies may be noted), pregnancy (especially the first trimester), lactation (breastfeeding), children under 6 years of age, hypersensitivity to oxazepam.

Use in Pregnancy and Lactation

Oxazepam has a toxic effect on the fetus and increases the risk of congenital malformations when used in the first trimester of pregnancy.

The use of therapeutic doses in later stages of pregnancy can cause depression of the newborn’s central nervous system. Continuous use during pregnancy can lead to physical dependence with the development of withdrawal syndrome in the newborn.

Children, especially at a young age, are very sensitive to the CNS depressant effect of benzodiazepines. Use immediately before or during childbirth can cause respiratory depression, decreased muscle tone, hypotension, hypothermia, and sluggish sucking syndrome in the newborn. Contraindicated during lactation.

Use in Hepatic Impairment

Use with caution in hepatic insufficiency.

Use in Renal Impairment

Use with caution in renal insufficiency.

Pediatric Use

Contraindicated in children under 6 years of age.

Geriatric Use

Use with caution in elderly patients.

Special Precautions

Any change in dose should be carried out under medical supervision.

Use with caution in cases of tendency to arterial hypotension, increased risk of drug dependence formation, in elderly patients, with hepatic and/or renal insufficiency, cerebral and spinal ataxias, hyperkinesis, tendency to abuse psychotropic drugs, organic brain diseases, psychosis (paradoxical reactions are possible), hypoproteinemia, established or suspected sleep apnea.

Oxazepam should not be used for a long time (for several months) due to the possibility of drug dependence development. During prolonged treatment, monitoring of liver function and peripheral blood status is necessary.

Effect on the ability to drive vehicles and mechanisms

During the treatment period, one should not drive vehicles or engage in other potentially hazardous activities that require increased attention; alcohol should not be consumed.

Drug Interactions

With simultaneous use with oral contraceptives, the effectiveness of oxazepam decreases.

With simultaneous use, the bioavailability of zidovudine is moderately increased and the frequency of headache development increases.

With simultaneous use with phenytoin, there is a risk of decreased plasma concentration of oxazepam.

With simultaneous use with ethanol, the depressant effect on the central nervous system is enhanced.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS